Near future
Contacts
  • Home
  • Tech
  • Health
  • Environment
  • Architecture
  • energia
  • Transportation
  • Spazio
  • AI
  • concepts
  • Gadgets
  • Italy Next
  • H+
May 21, 2022

Coronavirus / Russia-Ukraine

Near future

News to understand, anticipate, improve the future.

No Result
View All Result

News to understand, anticipate, improve the future.

Read in:  Chinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

New vaccine for Epstein Barr virus: human experimentation begins

If it works, the new Epstein Barr virus vaccine will protect people from mononucleosis and possibly multiple sclerosis.

Gianluca Ricciodi Gianluca Riccio
in Medicine
Share58Pin14Tweet36SendShare10ShareShare7
Epstein Barr virus

Epstein Barr virus

May 13, 2022
⚪ Reads in 3 minutes
A A

Epstein Barr virus (EBV) is a virus of the herpes family that spreads through saliva and which it affects about 9 out of 10 people, although many are unaware of it because they are generally asymptomatic.

Like other herpesviruses (including chickenpox, shingles, and cold sores) once Epstein Barr infects a person it stays in their body forever hiding in their cells, but can periodically reactivate causing new symptoms.

An insidious enemy

The Epstein Barr virus is primarily known to cause mononucleosis (also known as the "kissing disease"). It causes extreme fatigue, fever and sore throat, and can last for weeks or even months. 

Maybe you are also interested

Multiple sclerosis, new immunotherapy in phase 1 studies has stopped her

Green light for tests for T-Cell Skin Patches, anti Covid patches

First deadliest breast cancer vaccine begins human testing

We will grow vegetable vaccines to eat

However, EBV has long been associated with an increased risk of some cancers and autoimmune diseases, the worst of which is multiple sclerosis.

In January 2022, a Harvard team released the results of a study conducted on ten million young people. It is revealed that those infected with the Epstein Barr virus have 32 times more likely to develop multiple sclerosis. It was the first comprehensive study that provides compelling evidence for this causation.

"A big step," says the Italian Alberto Ascherio, a professor at the Harvard School of Public Health and lead author of the research. “It suggests that most cases of multiple sclerosis could be prevented by stopping Epstein Barr virus infection. Studying this virus better can lead to the discovery of a cure for multiple sclerosis: if you are not infected with it, the risk of developing it is practically zero ".

alberto ascherio epstein barr
The professor. Alberto Ascherio, one of the authors of the study that identified the correlation between Epstein Barr virus and multiple sclerosis

A vaccine against the Epstein Barr virus

The US National Institute of Allergy and Infectious Diseases (NIAID) has experimentation started phase 1 of an Epstein Barr virus vaccine. The vaccine targets a molecule found on the surface of the virus, called glycoprotein 350. It is the same molecule that the neutralizing antibodies of the immune system attack when there is an EBV infection.

In this study, the researchers will give 40 healthy young adults between the ages of 18 and 29 three doses of the Epstein Barr vaccine. The goal is to determine the safety of the vaccine and see what kind of immune response it requires. 

The fight has started

Developing herpesvirus vaccines is not easy, given their ability to "hide" from our immune system. In particular, Epstein Barr, which until a few months ago was not considered a priority.

However, the fact that it can cause multiple sclerosis has accelerated everyone's efforts. Moderna, one of the pharmaceutical companies that developed mRNA vaccines against Covid, is also currently testing a possible vaccine. And vaccines aside, they are being tested (with excellent results) also specific immunotherapies.

We may be close to knocking out the cause of one of the most disabling conditions, which can cause a lot of suffering to those with it.

tags: Multiple sclerosisvaccines
Previous post

Create 'renewable' or rather 'perpetual' bio photovoltaic cells

Next Post

Plastic recycling, shock report: "it doesn't work, and it will never work"

COLLABORATE

To submit articles, disclose the results of a research or scientific discoveries write to the editorial staff
  • Domus trimaran

    Domus, crazy zero-emission trimaran

    12128 Shares
    Share 4849 Tweet 3031
  • Plastic recycling, shock report: "it doesn't work, and it will never work"

    4373 Shares
    Share 1749 Tweet 1093
  • Create 'renewable' or rather 'perpetual' bio photovoltaic cells

    8267 Shares
    Share 3306 Tweet 2066
  • Hermeus tries it: hypersonic planes of 6000 kilometers per hour

    2742 Shares
    Share 1096 Tweet 685
  • Unreal Engine 5, crazy: it doesn't stand out from reality

    5839 Shares
    Share 2335 Tweet 1460

archive

Have a look here:

Spazio

Virgin Galactic unveils its VSS Imagine, and it's a pretty sight (in mirror)

Virgin Galactic takes another step towards space tourism by launching the VSS Imagine: more than a space plane, a platform ...

Read More

5 drugs that will prolong your youth, and help you save a lot of money

Disastrous

Scientist creates a toilet that turns feces into green energy

environmental management

Environmental management systems and ISO 14001: 2015 certifications for the industrial ecological transition

The era of the transparent battery is approaching

Next Post
plastic recycling

Plastic recycling, shock report: "it doesn't work, and it will never work"

The daily tomorrow

Futuroprossimo.it provides news on the future of technology, science and innovation: if there is something that is about to arrive, here it has already arrived. FuturoProssimo is part of the network ForwardTo, studies and skills for future scenarios.

Subscribe to our newsletter

Environment
Architecture
Artificial intelligence
Gadgets
concepts
Design

Staff
Archives
Advertising
Privacy Policy

Medicine
Spazio
Robotica
Work
Transportation
energia

To contact the FuturoProssimo editorial team, write to redazione@futuroprossimo.it

Chinese Version
Édition Française
Deutsche Ausgabe
Japanese version
English Edition
Edição Portuguesa
Русское издание
Spanish edition

The daily tomorrow

Futuroprossimo.it provides news on the future of technology, science and innovation: if there is something that is about to arrive, here it has already arrived. FuturoProssimo is part of the network ForwardTo, studies and skills for future scenarios.

Chinese Version
Édition Française
Deutsche Ausgabe
Japanese version
English Edition
Edição Portuguesa
Русское издание
Spanish edition

Staff
Archives
Advertising
Privacy Policy

Subscribe to our newsletter

To contact the FuturoProssimo editorial team, write to redazione@futuroprossimo.it

Categories

This work is distributed under license Creative Commons Attribution 4.0 International.
© 2021 Futuroprossimo

No Result
View All Result
  • Home
  • Tech
  • Health
  • Environment
  • Architecture
  • energia
  • Transportation
  • Spazio
  • AI
  • concepts
  • Gadgets
  • Italy Next
  • H+
This site uses cookies. By continuing to read it, you consent to their use.